Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas
dc.contributor.author | Sofela, AA | |
dc.contributor.author | Hilton, DA | |
dc.contributor.author | Ammoun, Sylwia | |
dc.contributor.author | Baiz, D | |
dc.contributor.author | Adams, Claire | |
dc.contributor.author | Ercolano, E | |
dc.contributor.author | Jenkinson, MD | |
dc.contributor.author | Kurian, KM | |
dc.contributor.author | Teo, M | |
dc.contributor.author | Whitfield, Peter | |
dc.contributor.author | Sahm, F | |
dc.contributor.author | Hanemann, Clemens Oliver | |
dc.date.accessioned | 2021-03-25T12:21:00Z | |
dc.date.issued | 2021-01-08 | |
dc.identifier.issn | 1661-6596 | |
dc.identifier.issn | 1422-0067 | |
dc.identifier.other | ARTN 560 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/16980 | |
dc.description.abstract |
<jats:p>There is an unmet need for the identification of biomarkers to aid in the diagnosis, clinical management, prognosis and follow-up of meningiomas. There is currently no consensus on the optimum management of WHO grade II meningiomas. In this study, we identified the calcium binding extracellular matrix glycoprotein, Fibulin-2, via mass-spectrometry-based proteomics, assessed its expression in grade I and II meningiomas and explored its potential as a grade II biomarker. A total of 87 grade I and 91 grade II different meningioma cells, tissue and plasma samples were used for the various experimental techniques employed to assess Fibulin-2 expression. The tumours were reviewed and classified according to the 2016 edition of the Classification of the Tumours of the central nervous system (CNS). Mass spectrometry proteomic analysis identified Fibulin-2 as a differentially expressed protein between grade I and II meningioma cell cultures. Fibulin-2 levels were further evaluated in meningioma cells using Western blotting and Real-time Quantitative Polymerase Chain Reaction (RT-qPCR); in meningioma tissues via immunohistochemistry and RT-qPCR; and in plasma via Enzyme-Linked Immunosorbent Assay (ELISA). Proteomic analyses (p < 0.05), Western blotting (p < 0.05) and RT-qPCR (p < 0.01) confirmed significantly higher Fibulin-2 (FBLN2) expression levels in grade II meningiomas compared to grade I. Fibulin-2 blood plasma levels were also significantly higher in grade II meningioma patients compared to grade I patients. This study suggests that elevated Fibulin-2 might be a novel grade II meningioma biomarker, when differentiating them from the grade I tumours. The trend of Fibulin-2 expression observed in plasma may serve as a useful non-invasive biomarker.</jats:p> | |
dc.format.extent | 560-560 | |
dc.format.medium | Electronic | |
dc.language | en | |
dc.language.iso | en | |
dc.publisher | MDPI AG | |
dc.subject | meningioma | |
dc.subject | atypical | |
dc.subject | benign | |
dc.subject | biomarker | |
dc.subject | plasma | |
dc.title | Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas | |
dc.type | journal-article | |
dc.type | Journal Article | |
plymouth.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000611326600001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008 | |
plymouth.issue | 2 | |
plymouth.volume | 22 | |
plymouth.publication-status | Published online | |
plymouth.journal | International Journal of Molecular Sciences | |
dc.identifier.doi | 10.3390/ijms22020560 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/Peninsula Medical School | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR | |
plymouth.organisational-group | /Plymouth/Research Groups/Plymouth Institute of Health and Care Research (PIHR) | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
plymouth.organisational-group | /Plymouth/Users by role/Researchers in ResearchFish submission | |
dc.publisher.place | Switzerland | |
dcterms.dateAccepted | 2021-01-05 | |
dc.rights.embargodate | 2021-3-27 | |
dc.identifier.eissn | 1422-0067 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.versionofrecord | 10.3390/ijms22020560 | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2021-01-08 | |
rioxxterms.type | Journal Article/Review |